Combination therapy with nivolumab and gemcitabine-cisplatin showed promising results in treating metastatic urothelial carcinoma with significantly improved overall survival and progression-free survival rates.
Nivolumab (Opdivo) with gemcitabine-cisplatin significantly improved overall and progression-free survival when given as a treatment for patients with metastatic urothelial carcinoma, according to the phase 3 CheckMate-901 study (NCT03036098) presented at the 2024 American Urological Association Annual Meeting.1
The treatment combination was approved by the FDA in March based on the results of CheckMate-901.2
“Cisplatin based chemotherapy has been the first-line standard of care for eligible patients with advanced urothelial carcinoma for decades.3-5 Although avelumab (Bavencio) has shown a survival benefit as maintenance therapy, only the subset of patients who do not have disease progression with first-line platinum-based chemotherapy are eligible.6,7
For the phase 3 CheckMate-901 trial, we evaluated up-front combination therapy with nivolumab plus gemcitabine cisplatin…followed by nivolumab monotherapy vs [gemcitabine-cisplatin] alone in eligible patients with previously untreated, advanced urothelial carcinoma,”8 said presenting author Guru Sonpavde, MD, medical director of Genitourinary Oncology, assistant director of the Clinical Research Unit and Christopher K. Glanz Chair for Bladder Cancer Research at the AdventHealth Cancer Institute in Orlando, Florida.
Patients 18 years of age or older with previously untreated, resectable or metastatic urothelial carcinoma involving the renal pelvis, ureter, bladder, or urethra who were cisplatin eligible and with an ECOG Performance Status of 0-1 were eligible for inclusion in the study. Participants “received [nivolumab] 360 mg plus [gemcitabine-cisplatin] every 3 [weeks] for up to 6 cycles followed by [nivolumab] 480 mg every 4 [weeks] until disease progression/unacceptable toxicity or up to a maximum of 2 years, or gemcitabine-cisplatin every 3 [weeks] for up to 6 cycles,” the investigators wrote.
The primary end points were overall survival (OS) and progression-free survival (PFS) per blinded independent central review. Key secondary end points included OS and PFS by PD-L1 of 1 or greater and health-related quality of life. Median study follow-up was 33.6 months (range, 7.4-62.4 months). A total of 304 patients were randomly assigned to each arm.
The investigators reported a median OS of 21.7 months (95% CI, 18.6-26.4) in the nivolumab plus gemcitabine-cisplatin arm compared with 18.9 months in the gemcitabine-cisplatin arm (95% CI, 14.7-22.4) (P = .0171). Median PFS per blinded independent central review was 7.9 months (95% CI, 7.6-9.5) in the nivolumab plus gemcitabine-cisplatin arm vs 7.6 months (95% CI, 6.1-7.8) in the gemcitabine-cisplatin arm.
In the nivolumab plus gemcitabine-cisplatin arm, 84% of patients had a 50% or greater reduction from baseline in sum of diameter of target lesions per blinded independent central review in all responders, 48% had a 75% or greater reduction, and 28% had a 90% or greater reduction. In the gemcitabine-cisplatin arm, 80% had a 50% or greater reduction, 40% had a 75% or greater reduction, and 20% had a 90% or greater reduction.
Any-grade adverse events (AEs) were observed in 97 patients in the nivolumab plus gemcitabine-cisplatin arm vs 93 in the gemcitabine-cisplatin alone arm. Grade 3 or higher AEs were seen in 62 patients in the nivolumab plus gemcitabine-cisplatin arm vs 52 in the gemcitabine-cisplatin arm.
“To summarize, [nivolumab] plus [gemcitabine-cisplatin] showed significant and clinically meaningful benefit in OS, PFS, and response over [gemcitabine-cisplatin] alone. As first-line treatment in advanced urothelial carcinoma, the CR rate approximately doubled for [nivolumab] plus [gemcitabine-cisplatin] to 21.7%, with a median duration of CR of 37.1 months. These benefits were attained with a finite duration of chemotherapy, up to 6 cycles, and a maximum of 2 years of nivolumab.
Analyses further characterizing patients who responded are warranted, especially in those who achieved CR. The safety in the responders was consistent with data in the ITT overall population.8 In the rapidly evolving treatment landscape, these results provide additional support for [nivolumab] plus [gemcitabine-cisplatin] as a first-line treatment option in patients with advanced urothelial carcinoma,” Sonpavde said.
DREAMM-8 Trial Demonstrates Benefits of Belantamab Mafodotin
October 3rd 2024Belantamab mafodotin plus pomalidomide and dexamethasone showed significant progression-free survival benefits and maintained quality of life in patients with relapsed/refractory multiple myeloma, as demonstrated in the DREAMM-8 trial.
Read More
Single CAR-T Infusion Shows Deep and Durable Responses in Relapsed Myeloma
October 2nd 2024A single infusion of the autologous GPRC5D-targeted CAR T-cell therapy BMS-986393 led to high response rates in patients with relapsed/refractory multiple myeloma who received between 1 and 3 prior lines of therapy.
Read More